Evidence map›Paper›PMID 33173313›Full record

ArticleOncoTargets and therapy2020

Upregulated

Zhenlin Huang, Yinghui Ding, Lu Zhang, Siyuan He, Zhankui Jia, Chaohui Gu, Tao Wang, Hao Li, Xiang Li, Zhibo Jin and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. MJournal of ovarian research · 2025
    Article
  5. Beyond linear: How circRNAs twist and turn Notch signaling.Journal of cell communication and signaling · 2025
    Review
  6. Review
  7. Article
  8. Circular RNAs and Cancers.Advances in experimental medicine and biology · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Zhenlin Huang *Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
Yinghui Ding *Department of Otology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
Lu Zhang *Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan 42000, People's Republic of China.
Siyuan HeDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
Zhankui JiaDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
Chaohui GuDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
Tao WangDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
Hao LiDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.ORCID 0000-0003-0541-562X
Xiang LiDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
Zhibo JinDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
Yafei DingDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
Jinjian YangDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 45000, People's Republic of China.
First Affiliated Hospital of Zhengzhou University · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCircular RNAs (circRNAs) are novel clusters of endogenous noncoding RNAs (ncRNAs) that are involved in the regulation of multiple biological processes in diverse types of cancers. However, the roles and precise mechanisms of circRNAs in renal cell carcinoma (RCC) occurrence and progression have not been clearly elucidated.

methodsWe identified the aberrantly expressed circRNAs in RCC by high-throughput RNA-seq assay and used qRT-PCR to test the expression level of circRNAs in RCC tissues. Loss-of-function experiments were executed to detect the biological roles of

resultsCircPDK1 was overexpressed in RCC tissues and positively associated with patient tumor metastasis and renal cell invasion. The in vivo functional assays also revealed that

conclusionCircPDK1 is aberrantly expressed in RCC and promotes the metastasis of RCC cells mainly through sponging

Indexed as

circPDK1metastasismiR-377-3PNOTCH1renal cell carcinoma

Identifiers

PMID33173313
PMCPMC7648593
OpenAlexW3094864165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.